Home > Healthcare > Biotechnology > Bioservices > Adeno Associated Virus Vectors Manufacturing Market

Adeno Associated Virus Vectors Manufacturing Market Trends

Report ID: GMI6876
Published Date: Oct 2023
Report Format: PDF

Download Free Sample

Adeno Associated Virus Vectors Manufacturing Market Trends

The market has experienced significant growth in recent years. The expanding pipeline of gene therapy has generated a surge in demand for adeno-associated virus (AAV) vectors, underscoring their pivotal role in this field. Researchers and biopharmaceutical companies are actively developing and testing new gene therapies for a wide range of conditions, including inherited genetic disorders, rare diseases, neurodegenerative disorders, and certain types of cancer. Each of these therapies typically requires a specific AAV vector tailored to the unique characteristics of the therapeutic gene and the target cells or tissues within the body Therefore, due to the safety and efficacy of AAV vectors, they have gained prominence in gene therapy and genetic medicine, thereby driving the market demand.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The global adeno associated virus vectors manufacturing industry value was USD 769.7 million in 2022 and will surpass USD 6.1 billion by 2032, attributed to expanding pipeline of gene therapy, advancements in vector production technology, and increased diversification of therapeutic areas.

The neurological disorders segment is anticipated to witness a growth rate of 22.3% between 2023 – 2032 as AAV vectors play a pivotal role in delivering therapeutic genes to specific cells within the nervous system, and they can either integrate into the host genome or persist as episomal structures, offering prolonged therapeutic benefits.

North America AAV vector manufacturing market is slated to reach USD 3 billion by end of 2032, owing to the region’s significant involvement in the clinical trials and commercialization of gene therapy products, many of which harness the potential of AAV vectors.

F. Hoffmann-La Roche (Spark Therapeutics), Biomarin Pharmaceutical, Oxford BioMedica plc, WuXi AppTec, YPOSKESI, Sarepta Therapeutics, Regenxbio Inc., Audentes Therapeutics, and 4D Molecular Therapeutics among others.